Injective, the blockchain platform behind the INJ token, has launched a new policy arm aimed at influencing how U.S. regulators approach decentralized finance, onchain derivatives, and stablecoins. The Injective Policy Institute will work to shape the regulatory framework for these fast-growing sectors.
Why a crypto company is setting up a policy shop
The institute's creation reflects a broader push by blockchain firms to engage directly with policymakers rather than reacting to rules after they're written. Injective's move puts it alongside a growing list of crypto projects that have established government affairs or policy divisions. The institute's stated goal is clear: to help define the rules for DeFi, derivatives settled on blockchain, and stablecoins — three areas that have drawn intense scrutiny from U.S. agencies.
Three areas of focus
The institute will concentrate on decentralized finance, which allows lending, trading, and other financial services without traditional intermediaries. U.S. regulators have questioned whether existing securities laws apply to many DeFi protocols. Onchain derivatives — contracts that track the value of assets and settle on a blockchain — also face an uncertain legal status. And stablecoins, digital tokens pegged to assets like the dollar, have been the subject of multiple congressional proposals and hearings. By targeting all three, the institute aims to present a unified industry perspective.
What comes next
The Injective Policy Institute will develop research and policy recommendations, though no specific timeline has been announced. Its success will depend on whether it can get regulators' attention and offer proposals that balance innovation with investor protection. The crypto industry has often struggled to get its voice heard in Washington, but dedicated policy shops are a relatively new tactic. Injective's bet is that early, consistent engagement will pay off as the U.S. moves closer to writing the rules for digital asset markets.
For now, the institute is setting up its team and laying out its agenda. How quickly it can produce actionable policy papers — and whether regulators will listen — remains the open question.
